



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Phone: 03-3817-5120

Fax: 03-3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No.08-05

February 1, 2008

Eisai Decides Additional Study for *Pariet*[®] for New Indication of Non-Erosive Gastro-Esophageal Reflux Disease in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) submitted an application in Japan for a new indication of non-erosive gastro-esophageal reflux disease for *Pariet*[®], a proton pump inhibitor, on March 27, 2006. As a result of consultation with the Pharmaceuticals and Medical Devices Agency, Eisai has made a decision to conduct additional study which will support the submitted data from the original application. Therefore, Eisai will withdraw the application at this time, and aims to resubmit it in FY2008.

Pariet[®] was launched first in Japan in 1997. Following that, the product began to be marketed in the Europe in 1998 and in the U.S. (by the brand name *AcipHex*[®]) in 1999. Currently, *Pariet*[®] is approved in 97 countries around the world.

According to the clinical studies, *Pariet*[®] has shown a rapid onset of action, a stable inhibitory effect on acid secretion with the approved indication in Japan including stomach ulcers, duodenal ulcers, gastro-esophageal reflux disease, and as a supplemental treatment for *Helicobacter pylori*